Chuk is an accomplished pharmaceutical scientist with over 5 years of experience in drug development across academia and the pharmaceutical industry. ✅ Senior Research Associate, Gilead Sciences Canada (2019 - 2021) 💡Contributed to the development and approval of Remdesivir for the treatment of COVID-19 💡Contributed to the ongoing development of Lenacapavir as a long-acting antiretroviral drug for improving medication adherence for HIV patients ✅ PhD Pharmaceutical Sciences - University of Toronto, Canada (2024) ✅ Research: Improving the clinical efficacy and safety profile of COVID-19 drugs ✅ Recipient of Canadian Institutes of Health Research Doctoral Award ($105K) - Ranked Top 11.65% out of 515 national applicants ✅ Recipient of over 20 international, national, and local awards (over $200K) for research, academic, and leadership accomplishments. ✅ MBA (93%) - Quantic School of Business and Technology, USA ✅ MSc Pharmacy (90%) - University of Saskatchewan Canada ✅ BSc Biochemistry (91%) - University of Benin Nigeria Founder and CEO - OneDrug. We are developing smart point-of-care medical device for identifying patients at-risk of adverse drug effects. Founder and CEO - Mirthomes. We are looking for strategic partners for our real estate portfolios. 🇨🇦🇳🇬